Paper - WANFANG MED ONLINE

You Position: Home > Paper

New perspectives of CTLs related immunotherapy in treatment of liver cancer

( views:18, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 15

DOI:: 10.11569/wcjd.v25.i15.1389

Key Word:: 原发性肝癌;细胞毒性T淋巴细胞;免疫反应;Hepatocellular carcinoma;Cytotoxic T lymphocytes;Immune reaction

Abstract： Abnormal polypeptides produced during the processing of a variety of proteins in cancer cells are presented by major histocompatibility complex class Ⅰ molecules to stimulate tumor specific cytotoxic T lymphocytes (CTLs) to produce immune reactions to tumor.However,various factors in hepatocellular carcinoma inhibit the function of CTLs or result in a nonfunctional state.In recent years,great progress has been made on the research of how to reactivate and enhance the function of CTLs in liver cancer.In this paper,we review the recent advances in CTLs related immunotherapy with regard to its ability to enhance antigen presentation and directly induce immune responses.

Reference

[1].Dendritic cell-based immunotherapy[J].2017,27(1).
[2]Takafumi Minami,Satoko Matsueda,Hiroko Takedatsu,etc.Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles[J].2007,56(5).
[3]Hiroyuki, Komori,Toru, Beppu,Hideo, Baba,etc.[Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma].[J].2010,68.
[4]Mónica, Alvarez-Fernández,René H, Medema.Novel functions of FoxM1: from molecular mechanisms to cancer therapy.[J].2013,3.
[5]Xing,S.,Lau,G.K.K.,Fu,B.,etc.Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma[J].2013,58(1).
[6]Huiting, Su,Bing, Li,Lan, Zheng,etc.Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.[J].2016,(30).
[7]Danijel Galun,Dragan Basaric,Marinko Zuvela,etc.Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols[J].2015,(20).
[8].Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism[J].2016,90(14).
[9]Matsui M,Kohyama S,Suda.A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.[J].2010,391(3).
[10]Guanzhen, Yu,Aidong, Zhou,Jianfei, Xue,etc.FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.[J].2015,6.
[11]Damianov A,Bindereif A,Bell M.p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor.[J].2002,21(11).
[12]李成敏,刘飞飞,伍春霞,等.人ASPH基因修饰树突状细胞介导CTLs对肝癌细胞系SMMC-7721的体外杀伤作用[J].2016,(6).
[13]Stefano, Colagrande,Andrea L, Inghilesi,Sami, Aburas,etc.Challenges of advanced hepatocellular carcinoma.[J].2016.
[14]Ton N, Schumacher,Robert D, Schreiber.Neoantigens in cancer immunotherapy.[J].2015,348(6230).
[15].Muc1 Immunotherapy Against a Metastatic Mammary Adenocarcinoma Model: Importance of Ifn-Gamma.[J].2016,(1).
[16]Bin, Sun,Zhi, Huang,Bi, Wang,etc.Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.[J].2017,23(Spec ).
[17]Nakatsura T,Kageshita T,Ito S,etc.Identification of glypican-3 as a novel tumor marker for melanoma.[J].2004,10(19).
[18]Yoshito Tomimaru,Sasmita Mishra,Howard Safran,etc.Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma[J].2015,33(10).
[19]Chen, Xin,Du, Yong,Hu, Qingqing,etc.Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4[J].2017,213(3).
[20]Hyung Joon Yim,Anna Suk-Fong Lok.Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005[J].2006,43(S1).
[21]Sarah M,Bray.Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.[J].2011,2011.
[22]Han, Seung-Soo,Lee, Jinjoo,Jung, Yideul,etc.Development of oral CTL vaccine using a CTP-integrated Sabin 1 poliovirus-based vector system[J].2015,33(38).
[23]Abu-Baker M. Abdel-Aal,Vani Lakshminarayanan,Pamela Thompson,etc.Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist[J].2014,15(10).
[24]Moreno, B. Homet,Ribas, A..Anti-programmed cell death protein-1/ligand-1 therapy in different cancers[J].2015,112(9).
[25]Gui-Qi, Zhu,Ke-Qing, Shi,Hua-Jian, Yu,etc.Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.[J].2015,6.
[26]Shao-Qiang Li,Jie Lin,Chao-Ying Qi,etc.GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.[J].2014,61(130).
[27]Kakimi, Kazuhiro,Karasaki, Takahiro,Matsushita, Hirokazu,etc.Advances in personalized cancer immunotherapy[J].2017,24(1).
[28].Combining Antigen-Specific CTLs with Ipilimumab Is Effective in Melanoma.[J].2016.
[29]Shi-Feng, Huang,Ding-Bin, Liu,Jian-Ming, Zeng,etc.Cloning, expression, purification, distribution and kinetics characterization of the bacterial beta-galactosidase fused to the cytoplasmic transduction peptide in vitro and in vivo.[J].2009,68(2).
[30]Lokody, Isabel.Signalling: FOXM1 and CENPF: co-pilots driving prostate cancer.[J].2014,14(7).
[31]Padmanee, Sharma,James P, Allison.The future of immune checkpoint therapy.[J].2015,348(6230).
[32]Vivek, Verma,Young, Kim,Min-Cheol, Lee,etc.Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.[J].2016,(26).
[33]Jia, Zhang,Jing, Zhang,Xiaohai, Cui,etc.FoxM1: a novel tumor biomarker of lung cancer.[J].2015,8(3).
[34]Pinho, Salome S.,Reis, Celso A..Glycosylation in cancer: mechanisms and clinical implications[J].2015,15(9).
[35]Rubina Novelli,Elena Gagliardini,Barbara Ruggiero,etc.Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis[J].2016,133(2).
[36]Ma, Lu,Shen, Xi,Gao, Yuan,etc.Blocking B7-1/CD28 Pathway Diminished Long-Range Brain Damage by Regulating the Immune and Inflammatory Responses in a Mouse Model of Intracerebral Hemorrhage[J].2016,41(7).
[37]Robbins, Paul F.,Lu, Yong-Chen.Targeting neoantigens for cancer immunotherapy[J].2016,28(7).
[38]Yoshifumi, Iwagami,Chiung-Kuei, Huang,Mark J, Olsen,etc.Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.[J].2016.
[39]Rosenberg, Steven A.,Restifo, Nicholas P..Adoptive cell transfer as personalized immunotherapy for human cancer[J].2015,348(Apr.3 TN.6230).